Jim Simons Mi Nk Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Mi Nk Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 101,707 shares of INKT stock, worth $966,216. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101,707

Previous 106,687 4.67%

Holding current value

$966,216

Previous $80,000 15.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$0.46 - $0.79 $2,290 - $3,934	-4,980 Reduced 4.67%	101,707 $68,000
Q3 2024 Nov 13, 2024	SELL	$0.74 - $1.14 $15,653 - $24,115	-21,154 Reduced 16.55%	106,687 $80,000
Q2 2024 Aug 09, 2024	BUY	$0.87 - $1.56 $19,673 - $35,276	22,613 Added 21.49%	127,841 $121,000
Q1 2024 May 13, 2024	BUY	$0.84 - $1.12 $11,077 - $14,769	13,187 Added 14.33%	105,228 $96,000
Q4 2023 Feb 13, 2024	BUY	$0.88 - $1.21 $30,216 - $41,547	34,337 Added 59.51%	92,041 $98,000
Q3 2023 Nov 14, 2023	SELL	$1.1 - $2.09 $96,606 - $183,552	-87,824 Reduced 60.35%	57,704 $63,000
Q2 2023 Aug 11, 2023	BUY	$0.89 - $3.33 $120,352 - $450,309	135,228 Added 1312.89%	145,528 $306,000
Q1 2023 May 12, 2023	BUY	$1.9 - $2.48 $19,570 - $25,544	10,300 New	10,300 $20,000
Q2 2022 Aug 12, 2022	SELL	$1.25 - $3.25 $32,200 - $83,720	-25,760 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.2 - $4.75 $20,548 - $44,365	-9,340 Reduced 26.61%	25,760 $58,000
Q4 2021 Feb 11, 2022	BUY	$4.12 - $20.03 $144,612 - $703,053	35,100 New	35,100 $157,000

Others Institutions Holding INKT

# of Institutions

Shares Held

810K

Call Options Held

Put Options Held

View Full List

About MiNK Therapeutics, Inc.

Ticker INKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,775,100
Market Cap $321M
Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...

More about INKT

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account